Detalhe da pesquisa
1.
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.
Cancer Immunol Immunother
; 72(2): 287-300, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35829790
2.
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.
Trends Immunol
; 39(7): 536-548, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29751996
3.
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
Nat Med
; 30(4): 1013-1022, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538867
4.
Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy.
Clin Immunol
; 148(2): 287-98, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811319
5.
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Cancer Immunol Immunother
; 62(2): 245-56, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22878899
6.
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(5): 509-17, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22326922
7.
GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.
Nat Commun
; 14(1): 3274, 2023 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37280238
8.
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.
Nat Commun
; 13(1): 3289, 2022 06 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672369
9.
Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic Treg reduction and effector T cell activation.
Sci Immunol
; 7(73): eabn8097, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857579
10.
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
Nat Med
; 28(8): 1619-1629, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35970920
11.
Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.
Cancer Immunol Immunother
; 59(9): 1313-23, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20499060
12.
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.
J Virol
; 83(8): 3450-62, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19193803
13.
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Clin Cancer Res
; 15(5): 1623-34, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19208793
14.
Combination of the 2A/furin technology with an animal component free cell line development platform process.
Appl Microbiol Biotechnol
; 87(4): 1517-24, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20461511
15.
Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Clin Immunol
; 133(2): 184-97, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19664962
16.
Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.
Clin Cancer Res
; 14(11): 3545-54, 2008 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519788
17.
Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Clin Cancer Res
; 14(12): 3933-41, 2008 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18559615
18.
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
Cancer Res
; 67(9): 4399-407, 2007 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17483354
19.
Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Exp Hematol
; 36(3): 319-28, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18279719
20.
Stable antibody expression at therapeutic levels using the 2A peptide.
Nat Biotechnol
; 23(5): 584-90, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15834403